Company’s 36-month beta value is 0.63.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BVS is 36.21M, and currently, short sellers hold a 2.17% ratio of that floaft. The average trading volume of BVS on May 07, 2024 was 141.18K shares.
BVS) stock’s latest price update
Bioventus Inc (NASDAQ: BVS)’s stock price has gone rise by 22.50 in comparison to its previous close of 4.00, however, the company has experienced a 23.74% increase in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-29 that DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2024 before the market opens on Tuesday, May 7, 2024. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.
BVS’s Market Performance
BVS’s stock has risen by 23.74% in the past week, with a monthly drop of -5.95% and a quarterly rise of 7.46%. The volatility ratio for the week is 3.89% while the volatility levels for the last 30 days are 4.75% for Bioventus Inc The simple moving average for the past 20 days is 12.44% for BVS’s stock, with a 16.31% simple moving average for the past 200 days.
Analysts’ Opinion of BVS
Many brokerage firms have already submitted their reports for BVS stocks, with Canaccord Genuity repeating the rating for BVS by listing it as a “Buy.” The predicted price for BVS in the upcoming period, according to Canaccord Genuity is $7 based on the research report published on December 07, 2023 of the previous year 2023.
Craig Hallum, on the other hand, stated in their research note that they expect to see BVS reach a price target of $6, previously predicting the price at $4. The rating they have provided for BVS stocks is “Buy” according to the report published on August 09th, 2023.
BVS Trading at 0.86% from the 50-Day Moving Average
After a stumble in the market that brought BVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.41% of loss for the given period.
Volatility was left at 4.75%, however, over the last 30 days, the volatility rate increased by 3.89%, as shares sank -1.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.20% upper at present.
During the last 5 trading sessions, BVS rose by +25.76%, which changed the moving average for the period of 200-days by +42.29% in comparison to the 20-day moving average, which settled at $4.35. In addition, Bioventus Inc saw -7.02% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BVS starting from Singleton Mark Leonard, who sale 4,000 shares at the price of $4.75 back on Apr 11 ’24. After this action, Singleton Mark Leonard now owns 34,665 shares of Bioventus Inc, valued at $19,000 using the latest closing price.
D’Adamio Anthony, the SVP & General Counsel of Bioventus Inc, sale 3,054 shares at $4.75 during a trade that took place back on Apr 11 ’24, which means that D’Adamio Anthony is holding 58,242 shares at $14,506 based on the most recent closing price.
Stock Fundamentals for BVS
Current profitability levels for the company are sitting at:
- 0.16 for the present operating margin
- 0.64 for the gross margin
The net margin for Bioventus Inc stands at -0.23. The total capital return value is set at 0.13. Equity return is now at value -39.47, with -8.86 for asset returns.
Based on Bioventus Inc (BVS), the company’s capital structure generated 0.7 points at debt to capital in total, while cash flow to debt ratio is standing at 0.04. The debt to equity ratio resting at 2.3. The interest coverage ratio of the stock is 1.96.
Currently, EBITDA for the company is 73.38 million with net debt to EBITDA at 2.67. When we switch over and look at the enterprise to sales, we see a ratio of 1.34. The receivables turnover for the company is 4.16for trailing twelve months and the total asset turnover is 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.53.
Conclusion
In a nutshell, Bioventus Inc (BVS) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
